A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Standard
A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. / Schrohl, Anne-Sofie; Müller, Volkmar; Christensen, Ib Jarle; Pantel, Klaus; Thomssen, Christoph; Bruenner, Nils.
In: TUMOR BIOL, Vol. 29, No. 3, 3, 2008, p. 181-187.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
AU - Schrohl, Anne-Sofie
AU - Müller, Volkmar
AU - Christensen, Ib Jarle
AU - Pantel, Klaus
AU - Thomssen, Christoph
AU - Bruenner, Nils
PY - 2008
Y1 - 2008
N2 - OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p <0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.
AB - OBJECTIVE: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been investigated as a potential tumour marker in breast cancer. Here we investigated the correlation between TIMP-1 in tumour tissue and plasma to evaluate whether TIMP-1 in plasma is actually a surrogate marker for TIMP-1 in primary tumours. Furthermore, we assessed whether increased TIMP-1 levels in plasma could be indicative of tumour progression in patients with advanced breast cancer. METHODS: Tumour tissue and preoperatively collected plasma samples from 96 primary breast cancer patients were included together with plasma samples from 46 patients with advanced disease. TIMP-1 levels were measured by ELISA. RESULTS: TIMP-1 levels in plasma (median 81.5 ng/ml, range 41.9-174.9) and tumour tissue (median 25.4 ng/mg of total protein, range 0-110.2) from primary breast cancer patients were not correlated (r = 0.05, p = 0.6). Plasma levels of TIMP-1 in primary breast cancer patients were significantly lower than levels in patients with advanced disease (median 108.7 ng/ml, range 59.7-560.7; p <0.0001). CONCLUSIONS: Our findings suggest that TIMP-1 release into the blood might be controlled by an active mechanism. They also point to plasma TIMP-1 as a potential marker for predicting tumour progression and for monitoring tumour burden in metastatic breast cancer patients.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 181
EP - 187
JO - TUMOR BIOL
JF - TUMOR BIOL
SN - 1010-4283
IS - 3
M1 - 3
ER -
